SCHEMBL14299

SCHEMBL14299

NCc1ccc(-n2cc3cc(-c4cccc(S(=O)(=O)N(CCOc5ccc(F)cc5)C5CCNCC5)c4)[nH]c3nc2=O)cc1

nearest known ligand 0.35

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
KIT P10721 4/20 0.35
SLC6A2 P23975 2/20 0.34
SLC6A4 P31645 2/20 0.34
KCNH2 Q12809 2/20 0.34
SLC6A3 Q01959 1/20 0.34
PSEN1 P49768 1/20 0.32
PSEN2 P49810 1/20 0.32
APH1B Q8WW43 1/20 0.32
NCSTN Q92542 1/20 0.32
APH1A Q96BI3 1/20 0.32
PSENEN Q9NZ42 1/20 0.32
F10 P00742 2/20 0.31
PDE3B Q13370 2/20 0.31
PDE3A Q14432 2/20 0.31
CCNT1 O60563 1/20 0.31
CDK9 P50750 1/20 0.31
NR1H2 P55055 1/20 0.31
ITGB3 P05106 1/20 0.30
ITGA2B P08514 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12062122 0.91 KIT (0.36) KITSLC6A2SLC6A4KCNH2SLC6A3
SCHEMBL12062130 0.87 SLC6A2 (0.35) KITSLC6A2SLC6A4KCNH2SLC6A3
SCHEMBL14505 0.87 SLC6A2 (0.36) KITSLC6A2SLC6A4KCNH2SLC6A3
SCHEMBL14511 0.85 SLC6A2 (0.34) KITSLC6A2SLC6A4KCNH2SLC6A3
SCHEMBL14777 0.85 SLC6A2 (0.34) SLC6A2SLC6A4KCNH2SLC6A3
SCHEMBL13652 0.84 SLC6A2 (0.34) KITSLC6A2SLC6A4KCNH2SLC6A3
SCHEMBL13650 0.84 SLC6A2 (0.34) KITSLC6A2SLC6A4KCNH2SLC6A3
SCHEMBL14410 0.84 CHEK2 (0.37) KITSLC6A2SLC6A4KCNH2SLC6A3
SCHEMBL14553 0.83 KCNH2 (0.35) KITSLC6A2SLC6A4KCNH2SLC6A3
SCHEMBL13941 0.83 SLC6A4 (0.36) KITSLC6A2SLC6A4KCNH2SLC6A3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2488525-B1 ANTIMICROBIAL COMPOUNDS AND METHODS OF MAKING AND USING THE SAME MELINTA THERAPEUTICS INC (US) 2018-04-25 EP disclosed
US-9193731-B2 Antimicrobial compounds and methods of making and using the same MELINTA THERAPEUTICS, INC. (US) 2015-11-24 US disclosed
US-9193731-B2 Antimicrobial compounds and methods of making and using the same MELINTA THERAPEUTICS, INC. (US) 2015-11-24 US disclosed
US-20120220566-A1 Antimicrobial Compounds and Methods of Making and Using the Same RIB-X PHARMACEUTICALS, INC. (US) 2012-08-30 US disclosed
US-20120220566-A1 Antimicrobial Compounds and Methods of Making and Using the Same RIB-X PHARMACEUTICALS, INC. (US) 2012-08-30 US disclosed
WO-2011047319-A2 ANTIMICROBIAL COMPOUNDS AND METHODS OF MAKING AND USING THE SAME RIB-X PHARMACEUTICALS, INC. (US) 2011-04-21 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120220566-A1 Antimicrobial Compounds and Methods of Making and Using the Same MPO, LPO, CAT KIT 3949/4885SLC6A2 3776/4885SLC6A4 4116/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.